http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 08:38:41 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html <p>Following the White House Executive Order on Monday strengthening the enforcement of defense procurement restrictions on critical minerals, DA Davidson analyst Matt Summerville shared an update highlighting stocks for which this development is incrementally positive.</p><p>The analyst commented, "In short, we believe our covered names in this space (ALM, GMTL, and MP) are all extremely well positioned with their own respective non-adversarial supply chains ramping as we speak. Additionally, we believe this announcement further emphasizes the billions of dollars’ worth of nearer-term optionality present at GMTL’s Tempiute tungsten project discussed in our update published this morning...we view this announcement as incrementally http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html Tue, 21 Jul 2026 08:38:41 -0400 ALM GMTL MP http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html <p>Following the White House Executive Order on Monday strengthening the enforcement of defense procurement restrictions on critical minerals, DA Davidson analyst Matt Summerville shared an update highlighting stocks for which this development is incrementally positive.</p><p>The analyst commented, "In short, we believe our covered names in this space (ALM, GMTL, and MP) are all extremely well positioned with their own respective non-adversarial supply chains ramping as we speak. Additionally, we believe this announcement further emphasizes the billions of dollars’ worth of nearer-term optionality present at GMTL’s Tempiute tungsten project discussed in our update published this morning...we view this announcement as incrementally http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html Tue, 21 Jul 2026 08:38:41 -0400 ALM GMTL MP http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html <p>Following the White House Executive Order on Monday strengthening the enforcement of defense procurement restrictions on critical minerals, DA Davidson analyst Matt Summerville shared an update highlighting stocks for which this development is incrementally positive.</p><p>The analyst commented, "In short, we believe our covered names in this space (ALM, GMTL, and MP) are all extremely well positioned with their own respective non-adversarial supply chains ramping as we speak. Additionally, we believe this announcement further emphasizes the billions of dollars’ worth of nearer-term optionality present at GMTL’s Tempiute tungsten project discussed in our update published this morning...we view this announcement as incrementally http://www.streetinsider.com/Analyst+Comments/Stocks+to+buy+as+White+House+executive+order+strengthens+critical+minerals+compliance/26792900.html Tue, 21 Jul 2026 08:38:41 -0400 ALM GMTL MP http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Almonty+Industries+Inc.+++For%3A+Jul+17/26786413.html si-local-file:///var/storage/secattach/20260720/26786413.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Almonty+Industries+Inc.+++For%3A+Jul+17/26786413.html Mon, 20 Jul 2026 06:01:00 -0400 ALM O.08451911 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Almonty+Industries+Inc.+++For%3A+Jul+17/26786413.html si-local-file:///var/storage/secattach/20260720/26786413.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Almonty+Industries+Inc.+++For%3A+Jul+17/26786413.html Mon, 20 Jul 2026 06:01:00 -0400 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Press+Releases/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html <ul class="bwlistdisc"> <li> <b>The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.</b> </li> <li> <b>Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.</b> </li> <li> <b>As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.</b> </li> </ul> <p> BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. http://www.streetinsider.com/Business+Wire/Almirall+Announces+EMA+Acceptance+for+Filing+of+Paediatric+Registration+of+Ebglyss+%28Lebrikizumab%29+in+Atopic+Dermatitis+in+Children+6+Months+and+Older/26786072.html Mon, 20 Jul 2026 04:00:00 -0400 A.31066700 ALM ALM O.22422661 O.52999069 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Press+Releases/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911 http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html <p> DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“<b>Almonty</b>” or the “<b>Company</b>”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “<b>Common Shares</b>”) from the Toronto Stock Exchange (the “<b>TSX</b>”) effective as of the close of trading on July 31, 2026 (the “<b>Delisting</b>”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “<b>Nasdaq</b>”) under the symbol ALM. </p><p> Given that the majority of the Company’s http://www.streetinsider.com/Business+Wire/Almonty+to+Voluntarily+Delist+From+TSX/26785270.html Fri, 17 Jul 2026 17:30:00 -0400 AII AII ALI1 ALI1 ALM O.08451911